AR098168A1 - Formulación estable de insulina glulisina - Google Patents
Formulación estable de insulina glulisinaInfo
- Publication number
- AR098168A1 AR098168A1 ARP140103985A ARP140103985A AR098168A1 AR 098168 A1 AR098168 A1 AR 098168A1 AR P140103985 A ARP140103985 A AR P140103985A AR P140103985 A ARP140103985 A AR P140103985A AR 098168 A1 AR098168 A1 AR 098168A1
- Authority
- AR
- Argentina
- Prior art keywords
- stable formulation
- glulisine insulin
- glulisine
- insulin
- pharmaceutical formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13306475 | 2013-10-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR098168A1 true AR098168A1 (es) | 2016-05-04 |
Family
ID=49552301
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140103985A AR098168A1 (es) | 2013-10-25 | 2014-10-23 | Formulación estable de insulina glulisina |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20150119323A1 (enExample) |
| EP (1) | EP3060240A1 (enExample) |
| JP (1) | JP6525987B2 (enExample) |
| KR (1) | KR20160074562A (enExample) |
| CN (1) | CN105705161A (enExample) |
| AR (1) | AR098168A1 (enExample) |
| AU (1) | AU2014338863A1 (enExample) |
| BR (1) | BR112016008736A2 (enExample) |
| CA (1) | CA2928320A1 (enExample) |
| CL (1) | CL2016000950A1 (enExample) |
| HK (1) | HK1225613A1 (enExample) |
| IL (1) | IL245109A0 (enExample) |
| MX (1) | MX2016005395A (enExample) |
| PH (1) | PH12016500720A1 (enExample) |
| RU (1) | RU2691059C2 (enExample) |
| SG (2) | SG11201602939QA (enExample) |
| TW (1) | TW201605489A (enExample) |
| WO (1) | WO2015059302A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5694779B2 (ja) | 2008-01-09 | 2015-04-01 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 極度に遅延した時間作用プロファイルを有する新規なインスリン誘導体 |
| LT3228320T (lt) | 2008-10-17 | 2020-03-10 | Sanofi-Aventis Deutschland Gmbh | Insulino ir glp-1 agonisto derinys |
| PL2498802T3 (pl) | 2009-11-13 | 2015-06-30 | Sanofi Aventis Deutschland | Kompozycja farmaceutyczna zawierająca agonistę GLP-1, insulinę i metioninę |
| EP2498801B1 (de) | 2009-11-13 | 2018-01-24 | Sanofi-Aventis Deutschland GmbH | HARMAZEUTISCHE ZUSAMMENSETZUNG UMFASSEND desPro36Exendin-4(1-39)-Lys6-NH2 UND METHIONIN |
| SI2611458T1 (sl) | 2010-08-30 | 2017-01-31 | Sanofi-Aventis Deutschland Gmbh | Uporaba AVE0010 za izdelavo zdravila za zdravljenje sladkorne bolezni tipa 2 |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| AR087744A1 (es) | 2011-09-01 | 2014-04-16 | Sanofi Aventis Deutschland | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa |
| CA2970200A1 (en) | 2014-12-12 | 2016-06-16 | Sanofi-Aventis Deutschland Gmbh | Insulin glargine/lixisenatide fixed ratio formulation |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| GB201607918D0 (en) * | 2016-05-06 | 2016-06-22 | Arecor Ltd | Novel formulations |
| IL277721B2 (en) | 2018-04-04 | 2024-03-01 | Arecor Ltd | Medical infusion pump system for the delivery of an insulin compound |
| FR3083700B1 (fr) * | 2018-07-13 | 2021-03-12 | Adocia | Formulation thermostable d'insuline humaine a21g |
| AR131148A1 (es) * | 2022-11-26 | 2025-02-19 | Obshchestvo S Ogranichennoy Otvetstvennostyu «Geropharm» | Composiciones de insulina de acción rápida (variantes de las mismas) |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5474978A (en) | 1994-06-16 | 1995-12-12 | Eli Lilly And Company | Insulin analog formulations |
| US5866538A (en) | 1996-06-20 | 1999-02-02 | Novo Nordisk A/S | Insulin preparations containing NaCl |
| US5948751A (en) | 1996-06-20 | 1999-09-07 | Novo Nordisk A/S | X14-mannitol |
| AR012894A1 (es) | 1997-06-13 | 2000-11-22 | Lilly Co Eli | Formulacion de insulina en solucion estable, su uso para preparar un medicamento y proceso para la preparacion de la misma. |
| DE10114178A1 (de) * | 2001-03-23 | 2002-10-10 | Aventis Pharma Gmbh | Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität |
| TWI394580B (zh) * | 2008-04-28 | 2013-05-01 | Halozyme Inc | 超快起作用胰島素組成物 |
| EP2308473A4 (en) * | 2008-07-01 | 2013-01-09 | Nitto Denko Corp | PHARMACEUTICAL COMPOSITION CONTAINING MICROPARTICLES WITH SURFACE COATING |
| EP3202394A1 (de) * | 2009-07-06 | 2017-08-09 | Sanofi-Aventis Deutschland GmbH | Wässrige insulinzubereitungen enthaltend methionin |
| MA33467B1 (fr) * | 2009-07-31 | 2012-07-03 | Sanofi Aventis Deutschland | Promédicaments comprenant un conjugué insuline-lieur |
| PL2498802T3 (pl) * | 2009-11-13 | 2015-06-30 | Sanofi Aventis Deutschland | Kompozycja farmaceutyczna zawierająca agonistę GLP-1, insulinę i metioninę |
| CN101912600B (zh) * | 2010-01-11 | 2014-01-29 | 杨国汉 | 改善胰岛素在溶液中稳定性的方法 |
| CA2839511C (en) * | 2011-06-17 | 2018-07-31 | Halozyme, Inc. | Stable formulations of a hyaluronan-degrading enzyme |
| US20130011378A1 (en) * | 2011-06-17 | 2013-01-10 | Tzung-Horng Yang | Stable formulations of a hyaluronan-degrading enzyme |
| CN104902922B (zh) * | 2012-11-13 | 2017-12-12 | 阿道恰公司 | 包含经取代阴离子化合物的速效胰岛素制剂 |
| AU2015205620A1 (en) * | 2014-01-09 | 2016-07-14 | Sanofi | Stabilized pharmaceutical formulations of insulin aspart |
-
2014
- 2014-10-23 AR ARP140103985A patent/AR098168A1/es unknown
- 2014-10-23 TW TW103136573A patent/TW201605489A/zh unknown
- 2014-10-24 RU RU2016119746A patent/RU2691059C2/ru not_active IP Right Cessation
- 2014-10-24 US US14/523,842 patent/US20150119323A1/en not_active Abandoned
- 2014-10-24 SG SG11201602939QA patent/SG11201602939QA/en unknown
- 2014-10-24 AU AU2014338863A patent/AU2014338863A1/en not_active Abandoned
- 2014-10-24 KR KR1020167012895A patent/KR20160074562A/ko not_active Withdrawn
- 2014-10-24 HK HK16113873.7A patent/HK1225613A1/zh unknown
- 2014-10-24 CA CA2928320A patent/CA2928320A1/en not_active Abandoned
- 2014-10-24 CN CN201480058603.5A patent/CN105705161A/zh active Pending
- 2014-10-24 MX MX2016005395A patent/MX2016005395A/es unknown
- 2014-10-24 BR BR112016008736A patent/BR112016008736A2/pt not_active Application Discontinuation
- 2014-10-24 SG SG10201803430SA patent/SG10201803430SA/en unknown
- 2014-10-24 WO PCT/EP2014/072915 patent/WO2015059302A1/en not_active Ceased
- 2014-10-24 EP EP14789560.1A patent/EP3060240A1/en not_active Withdrawn
- 2014-10-24 JP JP2016524503A patent/JP6525987B2/ja not_active Expired - Fee Related
-
2016
- 2016-04-14 IL IL245109A patent/IL245109A0/en unknown
- 2016-04-18 PH PH12016500720A patent/PH12016500720A1/en unknown
- 2016-04-21 CL CL2016000950A patent/CL2016000950A1/es unknown
-
2017
- 2017-10-27 US US15/656,839 patent/US20180036411A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP6525987B2 (ja) | 2019-06-05 |
| KR20160074562A (ko) | 2016-06-28 |
| IL245109A0 (en) | 2016-06-30 |
| RU2016119746A3 (enExample) | 2018-06-04 |
| AU2014338863A1 (en) | 2016-05-19 |
| CA2928320A1 (en) | 2015-04-30 |
| SG10201803430SA (en) | 2018-06-28 |
| TW201605489A (zh) | 2016-02-16 |
| HK1225613A1 (zh) | 2017-09-15 |
| US20180036411A1 (en) | 2018-02-08 |
| PH12016500720A1 (en) | 2016-05-30 |
| EP3060240A1 (en) | 2016-08-31 |
| SG11201602939QA (en) | 2016-05-30 |
| CL2016000950A1 (es) | 2016-11-04 |
| CN105705161A (zh) | 2016-06-22 |
| RU2691059C2 (ru) | 2019-06-10 |
| US20150119323A1 (en) | 2015-04-30 |
| MX2016005395A (es) | 2017-02-28 |
| WO2015059302A1 (en) | 2015-04-30 |
| RU2016119746A (ru) | 2017-11-30 |
| JP2016539921A (ja) | 2016-12-22 |
| BR112016008736A2 (pt) | 2017-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR098168A1 (es) | Formulación estable de insulina glulisina | |
| CY1121928T1 (el) | Φαρμακευτικη συνθεση υδροχλωρικης s-κεταμινης | |
| PH12019501931A1 (en) | Anti-pdl1 antibody formulations | |
| NI201500135A (es) | Composición farmacéutica de hidrocloruro de s-ketamina | |
| EA201591004A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| EA201591003A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| CO6680609A2 (es) | Composición acuosa que contiene bromhexina | |
| BR112016008576A2 (pt) | Formulações aquosas estáveis de anticorpos e forma farmacêutica de dosagem unitária | |
| UY35306A (es) | Formulaciones farmacéuticas estabilizadas de análogos de insulina y/o derivados de insulina. | |
| BR112018075140A2 (pt) | composição na forma de uma solução aquosa injetável, e, formulação de dose única a um ph de 7 a 7,8 | |
| UA115811C2 (uk) | Стабільний розчин об'єднаних баклофену, сорбіту і налтрексону для перорального застосування | |
| EP3009426A4 (en) | 4-ALKYNYL-IMIDAZOLE DERIVATIVE AND MEDICAMENT THEREFORE AS AN ACTIVE SUBSTANCE | |
| PE20160012A1 (es) | Tratamiento de enfermedades miopaticas y neurogenerativas por agregacion de proteina mediante administracion parenteral | |
| EA201591712A1 (ru) | Антибиотические композиции на основе цефтолозана | |
| CL2015003738A1 (es) | Formulación líquida estable de amg-416 (velcalcetida) | |
| MX2017009827A (es) | Formulacion farmaceutica. | |
| MX2019010330A (es) | Formulaciones con mejora de la estabilidad. | |
| MX388400B (es) | Una composición de dos componentes, que comprende ácido acetilsalicílico. | |
| CL2015003460A1 (es) | Composiciones oftálmicas acuosas tópicas que contienen un derivado de 1h-indol-1-carboxamida y uso de estas para el tratamiento de una enfermedad oftálmica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |